Sarepta Therapeutics, Inc. Stock Performance
as on March 14, 2026 at 6:59 am IST
Day's Low
Day's High
$16.40$17.59
0.12%
Downside
7.13%
Upside
52 Week's Low
52 Week's High
$10.42$103.3236.57%
Downside
529.21%
Upside
Sarepta Therapeutics, Inc. share price movements today
- Previous Close
- $17.04
- Open
- $17.41
- Volume
- 1.7M
- Day's Low - High
- $16.40 - $17.59
- 52 Week Low - High
- $10.42 - $103.32
Sarepta Therapeutics, Inc. Historical Returns
- 1 Month Return
- -7.81 %
- 3 Month Return
- -26.49 %
- 1 Year Return
- -83.13 %
- 3 Year Return
- -89.04 %
- 5 Year Return
- -80.58 %
Sarepta Therapeutics, Inc. Stock Fundamentals & Key Indicators
Check Sarepta Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$1.7B
EPS (TTM)
4.376
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
26.64%
PE Ratio (TTM)
276.74
Industry PE ratio
17.7675641025641
PEG Ratio
159.25
EBITDA
-613.3M
Revenue (TTM)
2.2B
Profit Margin
-32.45%
Return On Equity TTM
-53.47%
Sarepta Therapeutics, Inc. Stock Valuation
Track how Sarepta Therapeutics, Inc. P/E has moved over time to understand its valuation trends.
Sarepta Therapeutics, Inc. in the last 5 years
Lowest (-94.84x)
March 31, 2025
Industry (17.77x)
March 16, 2026
Today (276.74x)
March 16, 2026
Highest (110.59x)
September 30, 2024
Today’s Price to Earnings Ratio: 276.74x
Sarepta Therapeutics, Inc. vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Sarepta Therapeutics, Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $1.7B | -80.58% | 276.74 | -32.45% | |
| BUY | $41.6B | 117.98% | 135.09 | 8.45% | |
| BUY | $119.2B | 114.32% | 30.68 | 32.94% | |
| NA | $32.8B | NA | 115 | 5.37% | |
| BUY | $78.8B | 54.67% | 17.99 | 31.41% |
Stock Returns calculator for Sarepta Therapeutics, Inc. Stock including INR - Dollar returns
The Sarepta Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Sarepta Therapeutics, Inc. investment value today
Current value as on today
₹23,527
Returns
Returns from Sarepta Therapeutics, Inc. Stock
Dollar Returns*
₹6,632 (+6.63%)
Analyst Recommendation on Sarepta Therapeutics, Inc. Stock
Based on 29 analysts
82.76%
Buy
17.24%
Hold
0.00%
Sell
Based on 29 analysts, 82.76% of analysts recommend a 'BUY' rating for Sarepta Therapeutics, Inc.. Average target price of $20.61
Sarepta Therapeutics, Inc. Share Price Target
Get share price movements and forecasts by analysts on Sarepta Therapeutics, Inc..
What analysts predicted
20.33%UPSIDE
Target Price
$20.61
Current Price
$16.42
Analyzed by
29 Analysts
Target
$20.61
Sarepta Therapeutics, Inc. target price $20.61, a slight upside of 20.33% compared to current price of $16.42. According to 29 analysts rating.
Sarepta Therapeutics, Inc. Stock’s Investor Sentiment and Interest
Investment in Sarepta Therapeutics, Inc. Shares on INDmoney has dropped by -31.01% over the past 30 days, indicating reduced transactional activity.
Time period: to
Search interest for Sarepta Therapeutics, Inc. Stock has decreased by -17% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
Sarepta Therapeutics, Inc. Quarterly Profit & Loss
All numbers in Millions USD
Sarepta Therapeutics, Inc. Annual Profit & Loss
All numbers in Millions USD
Sarepta Therapeutics, Inc. Quarterly Cash Flow
All numbers in Millions USD
Sarepta Therapeutics, Inc. Annual Cash Flow
All numbers in Millions USD
Sarepta Therapeutics, Inc. News & Key Events
Today's Timeline - 26 February
Thu, 04:22 PM
-CEO Douglas Ingram plans to retire by end of 2026 amid company challenges and stock volatility concerns.
Thu, 08:00 PM
-Sarepta's Q4 revenue of $442.93 million beats estimates but reflects a significant year-over-year decline.
Thu, 08:59 PM
-Sarepta reports Q4 2025 adjusted loss of $3.58 per share, wider than estimates, with revenues down nearly 33% year-over-year.
Insights on Sarepta Therapeutics, Inc.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 2 quarters, 399.35M → 442.93M (in $), with an average increase of 9.8% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 65.2% return, outperforming this stock by 154.2%
- NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 29.6% return, outperforming this stock by 112.7%
NEGATIVE IMPACTPrice Dip
In the last 1 year, SRPT stock has moved down by -83.1%
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 3 quarters, 196.89M → -282.84M (in $), with an average decrease of 124.3% per quarter
About Sarepta Therapeutics, Inc.
| Organisation | Sarepta Therapeutics, Inc. |
| Headquarters | 215 First Street, Cambridge, MA, United States, 02142 |
| Industry | Health Technology |
| CEO | Mr. Douglas S. Ingram Esq., J.D. |
| E-voting on shares | Click here to vote |
Key Management of Sarepta Therapeutics, Inc.
Name | Title |
|---|---|
Ryan H. Wong | Executive VP & CFO |
Ms. Alison Nasisi | Executive VP & Chief People Officer |
Dr. Diane L. Berry Ph.D. | Executive VP and Chief of Global Policy & Advocacy Officer |
Mr. Douglas S. Ingram Esq., J.D. | CEO & Director |
Mr. Ian Michael Estepan | President & COO |
Dr. Louise R. Rodino-Klapac Ph.D. | President of Research & Development and Technical Operations |
Rachael Potter Ph.D. | Chief Scientific Officer |
Tamara Thornton | Director of Finance, Treasury & Investor Relations |
Ms. Cristin L. Rothfuss J.D. | Executive Vice President, General Counsel & Company Secretary |
Patrick Moss Pharm.D. | Executive VP & Chief Commercial Officer |
FAQs
What is Sarepta Therapeutics, Inc. share price today?
Sarepta Therapeutics, Inc. share price today is $16.42 as on at the close of the market. Sarepta Therapeutics, Inc. share today touched a day high of $17.59 and a low of $16.4.
What is the 52 week high and 52 week low for Sarepta Therapeutics, Inc. share?
Sarepta Therapeutics, Inc. share touched a 52 week high of $103.32 on and a 52 week low of $10.42 on . Sarepta Therapeutics, Inc. stock price today i.e. is closed at $16.42,which is 84.11% down from its 52 week high and 57.66% up from its 52 week low.
What is Sarepta Therapeutics, Inc.'s market capitalisation today?
Sarepta Therapeutics, Inc. market capitalisation is $0.00T as on .
How to invest in Sarepta Therapeutics, Inc. Stock (SRPT) from India?
- Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
- Step 2: Search for Sarepta Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Sarepta Therapeutics, Inc. Shares that will get you 0.0914 shares as per Sarepta Therapeutics, Inc. share price of $16.42 per share as on March 14, 2026 at 1:29 am IST.
What is the minimum amount required to buy Sarepta Therapeutics, Inc. Stock (SRPT) from India?
Indian investors can start investing in Sarepta Therapeutics, Inc. (SRPT) shares with as little as ₹92.45 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹924.50 in Sarepta Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Sarepta Therapeutics, Inc. share’s latest price of $16.42 as on March 14, 2026 at 1:29 am IST, you will get 0.6090 shares of Sarepta Therapeutics, Inc.. Learn more about
fractional shares .
What are the returns that Sarepta Therapeutics, Inc. has given to Indian investors in the last 5 years?
Sarepta Therapeutics, Inc. stock has given -80.58% share price returns and 27.37% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?